Vinblastine-Associated Pulmonary Toxicity in Patients Receiving Combination Therapy with Mitomycin and Cisplatin
| Autor: | Dan W. Luedke, Karen L. Hoelzer, Susan W. Luedke, Bruce R. Harrison |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Male
Lung Neoplasms Vinca Combination therapy medicine.drug_class Pulmonary toxicity Pilot Projects Adenocarcinoma Pharmacology Vinblastine 030226 pharmacology & pharmacy Mitomycins Vinca alkaloid 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans heterocyclic compounds Pharmacology (medical) 030212 general & internal medicine General Pharmacology Toxicology and Pharmaceutics Aged Cisplatin biology business.industry Pneumonia Middle Aged biology.organism_classification Regimen Toxicity Carcinoma Squamous Cell business medicine.drug |
| Zdroj: | Drug Intelligence & Clinical Pharmacy. 20:287-289 |
| ISSN: | 0012-6578 |
| DOI: | 10.1177/106002808602000415 |
| Popis: | Two of 33 patients entered in a local pilot study of mitomycin, vinblastine, and cisplatin for non-small cell lung cancer developed vinblastine-associated pulmonary toxicity. As with other reports of vinca alkaloid-related pulmonary toxicity, the regimen included mitomycin. Based on these cases and others previously reported, the incidence of abrupt pulmonary toxicity following vinca alkaloid administration as part of mitomycin/vinca alkaloid combination appears to be three to six percent. Suggestions for management are given. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|